Classification
- Anatomical main groupJAnti-infectives for systemic use
- Therapeutic subgroupJ07
- Pharmacological subgroupJ07A
- Chemical subgroupJ07AHMeningococcal vaccines
- Chemical substanceJ07AH09Meningococcus b, multicomponent vaccine
Where it is registered
Each register with its number of medicines and a few of them.
All medicines with Meningococcal group b vaccine
Every register, a page at a time. Strengths and packs are on each medicine’s page.
24 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Bexsero | United States | 0.5ML | Injection | Marketed | GlaxoSmithKline Biologicals |
| Trumenba | United States | 0.5ML | Injection | Marketed | Wyeth Pharmaceuticals LLC |
| Bexsero | European Union | Authorised | GSK Vaccines S.r.l. | ||
| Trumenba | European Union | Authorised | Pfizer Europe MA EEIG | ||
| PenmenvyCombination | United States | 25UG/0.5ML | Injection | Marketed | GlaxoSmithKline Biologicals |
| PenbrayaCombination | United States | 5UG | Injection | Marketed | Pfizer Ireland Pharmaceuticals Unlimited Company |
| Meningococcal Vaccine A&C VialCombination | Saudi Arabia | Authorised | Sanofi Pasteur | ||
| Meningococcal Vaccine A&C VialCombination | Saudi Arabia | Authorised | Sanofi Pasteur | ||
| MenveoCombination | United States | 0.5ML | Injection | Marketed | GlaxoSmithKline Biologicals |
| MenveoCombination | United States | 0.5ML | Injection | Marketed | GlaxoSmithKline Biologicals |
| MenactraCombination | United States | 48UG/.5ML | For Injection | Marketed | Sanofi Vaccines US Inc. |
| Menquadfi | United States | 0.5ML | Injection | Marketed | Sanofi Vaccines US Inc. |
| MenhibrixCombination | United States | 0.5ML | Injection | Withdrawn | GlaxoSmithKline Biologicals |
| Meningococcal Polysaccharide Vaccine Groups A & CCombination | Canada | 500 MCG / VIAL + 500 MCG / VIAL | Kit, Powder For Solution | Cancelled | Aventis Pasteur SA |
| MenQuadfiCombination | New Zealand | Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial | Funded | ||
| NimenrixCombination | New Zealand | Inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial | Funded | ||
| NimenrixCombination | Saudi Arabia | Authorised | Pfizer Manufacturing Belgium N.V. | ||
| TrumenbaCombination | Saudi Arabia | Authorised | Pfizer | ||
| MenomuneCombination | United States | 50UG/.5ML | For Injection | Withdrawn | Sanofi Vaccines US Inc. |
| Menomune-A | United States | 0.5ML | For Injection | Withdrawn | Sanofi Vaccines US Inc. |
| Menomune-C | United States | 0.5ML | For Injection | Withdrawn | Sanofi Vaccines US Inc. |
| Menomune-A/CCombination | United States | 50UG/.5ML | For Injection | Withdrawn | Sanofi Vaccines US Inc. |
| Menomune-A/CCombination | United States | 50UG/.5ML | For Injection | Withdrawn | Sanofi Vaccines US Inc. |
| Penbraya | European Union | Withdrawn | Pfizer Europe MA EEIG |